

REMARKS

This amendment is responsive to the Final Rejection dated June 4, 2003. Claim 1 is amended herein. Claims 2 and 11 have been canceled without prejudice to resubmission. No new claims are added. Claims 1 and 3-10 will be pending in the present application upon entry of the amendments herein.

All of the amendments proposed herein are proposed for the purpose of overcoming the outstanding rejections and thus entry of the amendments for the purpose of placing the application in condition for allowance, is requested.

Double Patenting

The pending claims of present application have been provisionally rejected under the judicially-created doctrine of obviousness-type double patenting, as allegedly unpatentable over claims 1 through 7 and 16 through 20 of co-pending application nos. 10/132,642 and 10/045,790. Although the application does not agree with this rejection, in order to expedite and streamline prosecution of the present application, the applicant will submit a terminal disclaimer to overcome this rejection should a patent be issued on co-pending application 10/045,790, before the issuance of a patent on the present application.

No Notice of Allowance has been issued in either of co-pending application nos. 10/132,642 and 10/045,790, as of the mailing of this response and thus it is not necessary to submit a Terminal Disclaimer at this time.

The Rejections under 35 U.S.C. § 112

Claims 1, 4, and 6-10 have been rejected under 35 U.S.C. § 112, first paragraph, as allegedly lacking enablement for “compounds that inhibit at least one of cell differentiation and cell proliferation.” Applicant respectfully requests entry of the amendments to claim 1 and withdrawal of this rejection upon reconsideration, in view of the amendments to claim 1.

More specifically, the subject matter of claim 2 has been inserted into claim 1 to specify the compounds that inhibit at least one of cell differentiation and cell proliferation. Since claim 2 was not included in this rejection, it is considered that the insertion of the subject matter of claim 2 into claim 1 overcomes the rejection. Favorable consideration and withdrawal of the rejection is requested.

Claims 1 to 11 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly lacking enablement for the term “prevention,” and also as allegedly failing to convey that the Applicant had possession of the claimed invention when the application was filed. This rejection, at least insofar as it applies to claims 1 and 11, as amended, is respectfully traversed and reconsideration is requested for the reasons, which follow.

Independent claim 11 has been canceled without prejudice to resubmission thereby obviating the rejection of claim 11. Claim 1 has been amended to delete the reference to “prevention” in order to obviate the rejection. Accordingly, for these reasons, entry of the amendments and withdrawal of the rejection is requested.

The Rejections under 35 U.S.C. § 103


Claim 11 has been rejected as allegedly obvious over U.S. Patent No. 6,162,801, issued to Kita (hereinafter “Kita”), the article by Darr, D., *et al.*, in the *British Journal of Dermatology*, 1992, 127, 247-253 (hereinafter “Darr”), and U.S. Patent No. 5,972,359, issued to Sine et al. (hereinafter “Sine”), in view of U.S. Patent No. 6,048,886, issued to Neigut (hereinafter “Neigut”), U.S. Patent No. 5,876,737, issued to Schönrock et al. (hereinafter “Schönrock”), and U.S. Patent No. 5,952,391, issued to Gers-Barlag et al. (hereinafter “Gers-Barlag”).

Claim 11 has been canceled without prejudice to resubmission thereby obviating this rejection.

Conclusion

In view of the foregoing amendments and remarks, Applicant respectfully submits that upon entry of this amendment, all of the pending claims are in condition for allowance and respectfully requests a favorable Office Action so indicating.

Respectfully submitted,


Kevin J. Dunleavy
Registration No. 32,024

Dated: September 4, 2003

KNOBLE & YOSHIDA, LLC (Customer No. 21,302)
Eight Penn Center, Suite 1350
1628 John F. Kennedy Blvd.
Philadelphia, PA 19103
Direct Dial No.: (215) 599-0606
Facsimile No.: (215) 599-0601
e-mail: kjdunleavy@patentwise.com